




PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. :	10/673,618)	CERTIFICATE OF MAILING
Applicant :	Hector F. DeLuca)	I hereby certify that this correspondence is
)	being deposited with the United States
Filed :	September 29, 2003)	Postal Service with sufficient postage as
Title :	Use of 2 α -Methyl-19-)	first class mail in an envelope addressed to:
	Nor-20(S)-1 α ,25-)	Commissioner of Patents, P.O. Box 1450,
	Dihydroxyvitamin D ₃ to)	Alexandria, VA 22313-1450, on this 23rd
	Increase Bone Strength)	day of December, 2003.
)	
TC/A.U. :)	
Examiner :)	 December 23, 2003
)	Dorothy A. Hauser Date
Docket No. :	1256-00922)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop: IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references listed on the enclosed PTO Form 1449 are being submitted in the above-identified patent application in accordance with 37 CFR 1.97(b)(3).


A copy of each of the listed references is enclosed in compliance with the rules.

Respectfully submitted,

ANDRUS, SCEALES, STARKE & SAWALL, LLP

By 
Thomas M. Wozny
Reg. No. 28,922

Andrus, Sceales, Starke & Sawall, LLP
100 East Wisconsin Avenue, Suite 1100
Milwaukee, WI 53202
(414) 271-7590




Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 1256-00922	Appln. No.: 10/673,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Hector F. DeLuca et al	
		Filing Date September 29, 2003	Group Art Unit

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,666,634	05-19-87	Miyamoto et al	260	397	
		5,086,191	02-04-92	DeLuca et al	552	653	
		5,237,110	08-17-93	DeLuca et al	568	665	
		5,246,925	09-21-93	DeLuca et al	514	167	
		5,536,713	07-16-96	DeLuca et al	514	167	
		5,587,497	12-24-96	DeLuca et al	552	653	
		5,945,410	08-31-99	DeLuca et al	514	167	

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							Yes	No
		0184206	12-85	Europe				
		0078704	04-87	Europe				
		0387077	09-90	Europe				
		0474517	11-92	Europe				
		0480572	04-92	Europe				
		0516410	12-92	Europe				
		WO90/09991	09-90	PCT				
		WO96/01811	01-96	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Chemical Abstracts, XP-002066055, Vol. 121, No. 21, November 21, 1994.
	Posner et al, "2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D ₃ -Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing", <i>Journal of Organic Chemistry</i> , 60, pp. 4617-4628, 1995.
	Slatopolsky et al, "A New Analog of Calcitriol, 19-Nor-1,25-(OH) ₂ D ₂ Suppresses Parathyroid Hormone Secretion in Uremic Rats in the Absence of Hypercalcemia", <i>American Journal of Kidney Disorders</i> , 26(5), 832-60, 1995.



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 1256-00922	Appln. No.: 10/673,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Hector F. DeLuca et al	
		Filing Date September 29, 2003	Group Art Unit

	Posner et al, "Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1 α ,2 α ,25-Trihydroxyvitamin D ₃ ", <i>Journal of Organic Chemistry</i> , 56, pp. 4339-4341, April 15, 1995.		
	Chemical Abstracts, "Chemistry of Synthetic High Polymers", Vol. 110, No. 10, Abstract 110: 82505v, March 6, 1989.		
	Okano et al, "Regulatory Activities of 2 β -(3-Hydroxypropoxy)-1 α ,25-Dihydroxyvitamin D ₃ . A Novel Synthetic Vitamin D ₃ Derivative on Calcium Metabolism", <i>Biochemical and Biophysical Research Communications</i> , Vol. 163, No. 3, pp. 1444-1449, September 29, 1989.		
	Bouillon et al, "Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D ₃ ", <i>Bioactivity of 19-Nor-Pre D</i> , Vol. 8, No. 8, pp. 1009-1015, 1993.		
	Sarandeses et al, "Synthesis of 1 α ,25-Dihydroxy-19-Norprevitamin D ₃ ", <i>tetrahedron Letters</i> , pp. 5445-5448, April 1992.		
	Perlman et al, "1 α ,25-Dihydroxy-19-Nor-Vitamin D ₃ . A Novel Vitamin D-Related Compound with Potential Therapeutic Activity", <i>Tetrahedron Letters</i> , Vol. 31, No. 13, pp. 1823-1824, February 1990.		
	Baggiolini et al, "Stereochemical Total Synthesis of 1 α ,25-Dihydroxycholecalciferol and 1 β ,25-Dihydroxyrocalciferol", <i>Journal of Organic Chemistry</i> , 51, pp. 3098-3108, 1986.		
	Kiegiel et al, "Chemical Conversion of Vitamin D ₃ to its 1,25-Dihydroxy Metabolite", <i>Tetrahedron Letters</i> , Vol. 31, No. 43, pp. 6057-60660, 1991.		
	Peacock, <i>Journal of Bone and Mineral Research</i> , 1991, Vol. 6, Supplement 2, pp. S77-S84.		
	Hoiseth et al, <i>Acta Radiologica</i> , 1990, Vol. 31, No. 6, pp. 626-627.		
	Merck Manual, 16th Ed., 1992, page 1357.		
EXAMINER		DATE CONSIDERED	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to client.			



PTO/SB/21 (08-03)
Approved for use through 08/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/673,618
	Filing Date	September 29, 2003
	First Named Inventor	Hector F. DeLuca
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	1256-00922

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form ✓ <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Thomas M. Wozny, Reg. No. 28,922 Andrus, Sceales, Starke & Sawah, LLP	
Signature		
Date	December 23, 2003	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Dorothy A. Hauser		
Signature		Date	December 23, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.